CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 73,220	$ 159,973
Short-term investments	518,766	496,788
Contracts receivable	26,313	11,102
Inventories	7,085	8,033
Investment in Regulus Therapeutics Inc.	47,426	52,096
Other current assets	8,353	7,518
Total current assets	681,163	735,510
Property, plant and equipment, net	88,068	86,198
Licenses, net	3,160	4,572
Patents, net	16,879	15,517
Deposits and other assets	4,533	5,359
Total assets	793,803	847,156
Current liabilities:
Accounts payable	15,627	11,009
Accrued compensation	7,164	12,168
Accrued liabilities	29,140	22,092
Current portion of long-term obligations	3,667	4,408
Current portion of deferred contract revenue	51,727	48,135
Total current liabilities	107,325	97,812
Long-term deferred contract revenue	110,614	142,790
2 3/4 percent convertible senior notes	155,437	150,334
Long-term obligations, less current portion	4,039	6,542
Long-term financing liability for leased facility	71,616	71,288
Total liabilities	449,031	468,766
Stockholders' equity:
Common stock, $0.001 par value; 300,000,000 shares authorized, 117,990,371 and 116,471,371 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively	118	116
Additional paid-in capital	1,365,407	1,324,804
Accumulated other comprehensive income	16,894	21,080
Accumulated deficit	(1,037,647)	(967,610)
Total stockholders' equity	344,772	378,390
Total liabilities and stockholders' equity	$ 793,803	$ 847,156